Drug
Vociprotafib clinical trials
Also written RMC-4630 and SAR442720.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Revolution Medicines, Inc. (2) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vociprotafib is read from its arms, and is right about nine times in ten.
Testing it · 3
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedPhase 2Revolution Medicines, Inc.NCT05054725Written as RMC-4630
- Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersTerminatedPhase 1The Netherlands Cancer InstituteNCT04916236Written as RMC-4630
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsStatus unknownPhase 1Revolution Medicines, Inc.NCT03634982Written as RMC-4630
Given in every arm · 3 — vociprotafib is usual care beside what is tested
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as RMC-4630
- Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesTerminatedPhase 1/2SanofiNCT04418661Written as Vociprotafib
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedPhase 1/2Revolution Medicines, Inc.NCT03989115Written as RMC-4630
Codes
What other systems call vociprotafib · ClinicalTrials.gg INT016178
- UNII (FDA) C4YBF9170LVOCIPROTAFIBOne source FDA
- NCI Thesaurus C155850VociprotafibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C4YBF9170L | VOCIPROTAFIB | One source FDA |
| NCI Thesaurus | C155850 | Vociprotafib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.